

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com **https:**//www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 66678

Title: Gut Dysbiosis and Systemic Inflammation Promote Cardiomyocyte Abnormalities

in an Experimental Model of Steatohepatitis

Reviewer's code: 05867627 Position: Peer Reviewer Academic degree: MD

**Professional title:** Doctor

Reviewer's Country/Territory: Portugal

Author's Country/Territory: Brazil

Manuscript submission date: 2021-04-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-03 14:33

Reviewer performed review: 2021-04-15 16:02

**Review time:** 12 Days and 1 Hour

Scientific quality	[ Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous  Conflicts-of-Interest: [ ] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

## SPECIFIC COMMENTS TO AUTHORS

It is already scientific knowledge that the gut microbiota influences thousands of mechanisms in our body. It even influences the prognosis of diseases such as cardiovascular diseases (CVD), however much remains to be discovered. manuscript the authors tried to evaluate the relationship between the gut dysbiosis and CVD, in an experimental model of steatohepatitis, to prove that there is in fact a link between all of this. Through the chosen methods, the authors demonstrated an evident link in how MAFLD is a risk factor for the development of CVD, and that metabolites of the gut microbiota can translocate through the intestinal barrier to the liver, causing several inflammatory responses. This is a fascinating discovery, knowing that not only the microbial metabolites, but also the intestinal bacteria themselves can cross the intestinal barrier and reach the liver, is one of the key points to better understand how the intestinal microbiota can interfere in so many physiological and pathological situations in our organism. The choice of several different methods from each other allows a greater approach to the topic and one thus we can have better and more reliable results. The study's conclusions demonstrate with precision which checkpoints the authors reached and summarize the data this study provide. With all of this, here comes a great opportunity to start foccusing on new approaches aimed at directing the gut microbiota as a potencial therapeutical target.